Valuation: Veru Inc.

Market Cap 50.08M 43.85M 40.48M 37.8M 71.16M 4.73B 72.78M 487M 188M 2.34B 188M 184M 8.11B P/E 2026 *
-3.07x
P/E 2027 * -3.17x
Enterprise Value 50.08M 43.85M 40.48M 37.8M 71.16M 4.73B 72.78M 487M 188M 2.34B 188M 184M 8.11B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.01%
Yield 2026 *
-
Yield 2027 * -
1 day+3.65%
1 week+5.41%
Current month+31.65%
1 month+31.65%
3 months+49.28%
6 months+41.18%
Current year+45.79%
1 week 2.87
Extreme 2.8712
3.29
1 month 2.11
Extreme 2.11
7.33
Current year 2.05
Extreme 2.05
7.33
1 year 2.05
Extreme 2.05
7.33
3 years 2.05
Extreme 2.05
19.2
5 years 2.05
Extreme 2.05
245.5
10 years 2.05
Extreme 2.05
245.7
Manager TitleAgeSince
Chief Executive Officer 65 2016-10-30
Director of Finance/CFO 67 2012-12-31
Chief Tech/Sci/R&D Officer 64 2018-03-31
Director TitleAgeSince
Chairman 65 2018-02-28
Director/Board Member 68 2016-09-30
Director/Board Member 68 2018-02-28
Date Insider Type Main position Quantity % Market Cap.
05-03Free

Director

160,000 0.9969%
05-03Free

Director

100,000 0.6230%
05-03Free

Chief Financial Officer

164,000 1.0218%
Change 5-day change 1-year change 3-year change Capi.($)
+3.65%+5.41%-46.35%-73.56% 50.08M
+2.88%-0.62%+71.99%+127.35% 55.78B
+6.76%+18.10%+91.66%+104.09% 55.66B
+3.33%+4.51%-11.68%-11.91% 23.84B
+1.32%+6.22%+5.28%+415.45% 22.7B
+6.65%+7.26%+39.35%-28.97% 16.12B
-0.89%+5.71%+24.30%+186.29% 13.64B
+9.96%+15.98%+157.65%+310.89% 14.8B
+2.85%+2.81%+75.32%+139.44% 12.16B
+6.17%+10.22%+163.15%+166.44% 11.85B
Average +4.27%+7.20%+57.07%+133.55% 22.66B
Weighted average by Cap. +4.40%+7.70%+66.66%+142.91%

Financials

2026 *2027 *
Net sales - -
Net income -25.1M -21.98M -20.29M -18.95M -35.67M -2.37B -36.48M -244M -94.26M -1.17B -94.26M -92.19M -4.06B -37.1M -32.48M -29.99M -28M -52.72M -3.51B -53.92M -361M -139M -1.73B -139M -136M -6.01B
Net Debt - -
Logo Veru Inc.
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Employees
20
Date Price Change Volume
26-06-29 US$3.120 +3.65% 432,577
26-06-26 US$3.010 +2.38% 253,414
26-06-25 US$2.940 -1.01% 215,033
26-06-24 US$2.970 -2.30% 262,381
26-06-23 US$3.040 +2.70% 344,974
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.120USD
Average target price
24.50USD
Spread / Average Target
+685.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VERU Stock